116 related articles for article (PubMed ID: 28523296)
1. A systematic review of the possible carcinogenic role of the aristolochic acid.
Bara T; Gurzu S; Sugimura H; Bara T; Beleaua MA; Jung I
Rom J Morphol Embryol; 2017; 58(1):41-44. PubMed ID: 28523296
[TBL] [Abstract][Full Text] [Related]
2. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
5. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
6. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.
Cosyns JP
Drug Saf; 2003; 26(1):33-48. PubMed ID: 12495362
[TBL] [Abstract][Full Text] [Related]
8. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
9. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
Nault JC; Letouzé E
Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
11. [Aristolochic acid nephropathy ("Chinese herb nephropathy")].
Nortier J; Pozdzik A; Roumeguere T; Vanherweghem JL
Nephrol Ther; 2015 Dec; 11(7):574-88. PubMed ID: 26515658
[TBL] [Abstract][Full Text] [Related]
12. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
[TBL] [Abstract][Full Text] [Related]
13. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
Boot A; Jiang N; Rozen SG
Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
[TBL] [Abstract][Full Text] [Related]
14. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
Chen CH; Grollman AP; Huang CY; Shun CT; Sidorenko VS; Hashimoto K; Moriya M; Turesky RJ; Yun BH; Tsai K; Wu S; Chuang PY; Tang CH; Yang WH; Tzai TS; Tsai YS; Dickman KG; Pu YS
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):317-325. PubMed ID: 33277322
[TBL] [Abstract][Full Text] [Related]
15. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
[TBL] [Abstract][Full Text] [Related]
16. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.
Yang HY; Yang CC; Wu CY; Wang LJ; Lu KL
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261684
[TBL] [Abstract][Full Text] [Related]
17. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.
Ng AWT; Poon SL; Huang MN; Lim JQ; Boot A; Yu W; Suzuki Y; Thangaraju S; Ng CCY; Tan P; Pang ST; Huang HY; Yu MC; Lee PH; Hsieh SY; Chang AY; Teh BT; Rozen SG
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046434
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction.
Wang Y; Meng F; Arlt VM; Mei N; Chen T; Parsons BL
Mutagenesis; 2011 Sep; 26(5):619-28. PubMed ID: 21642617
[TBL] [Abstract][Full Text] [Related]
19. [Aristolochic acid nephropathy].
Witkowicz J
Przegl Lek; 2009; 66(5):253-6. PubMed ID: 19739583
[TBL] [Abstract][Full Text] [Related]
20. Recognition of the toxicity of aristolochic acid.
Zhang HM; Zhao XH; Sun ZH; Li GC; Liu GC; Sun LR; Hou JQ; Zhou W
J Clin Pharm Ther; 2019 Apr; 44(2):157-162. PubMed ID: 30548302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
